DIVINCELL’s Post

This week Aanastra Inc and DIVINCELL will be at the Advancing Gene and Cell Therapies for Cancer Conference (American Society of Gene & Cell Therapy), taking place October 16-17, 2024, in Philadelphia,. https://lnkd.in/eswMGcxg We will present our RNA-based therapeutic platform to target aberrant genetic disorders and oncogenes in cancer  ▶ "mRNA-mediated Rescue of Lost Tumor Suppressor Function in Mutated p53 or BRCA1 Tumors is a Potent New Strategy for Cancer Therapy Delivered with Tumor-Targeted Peptide (non-LNP) Nanoparticles ". Abstract 24. ▶ "In Vivo CRISPR Gene Editing of KRAS Mutant Tumors with Tumor-Targeted (non-LNP) Peptide-based Nanoparticles Causes Strong Tumor Regressions with Only 2 Doses and Overcomes Resistance to Existing Small-Molecule KRAS Inhibitors". Abstract 25. #p53 #KRAS #CRISPR #BRCA-1 #BRCAness #nanotechnology #drugdelivery #mRNA #ASGCTAdvancing24 #ASGCT #geneediting

Next week DIVINCELL and Aanastra Inc will be at the RNA Leaders USA Congress,  taking place September 4-5, 2024, in San Diego. https://lnkd.in/dhTfJ4VB We will be presenting our “Peptide-Based Nanoparticle-Platform for Targeted Delivery of Functional mRNAs : application for mRNA rescue and gene editing”. #mRNA #RNAleaders #drugdelivery #geneediting

Next week DIVINCELL and Aanastra Inc will be at the American Society of Gene & Cell Therapy Gene and Cell Therapies (@ASGCT), 27th Annual Meeting, taking place May 7-11, 2024, in Baltimore, Maryland. https://lnkd.in/dHgkVjV We will be presenting oral and posters highlighting preclinical data supporting our novel RNA-based therapeutic strategy to target aberrant genes and oncogenes : ▶Oral presentation" KRAS Mutant Gene Editing Abolishes Tumor Growth In Vivo and Overcomes Acquired Resistance to KRASG12C and KRASG12D Small Molecule Inhibitors" Session: Targeted Gene and Cell Therapy II, Abstract: 415, May 11th, 10:15 AM - 12:00 PM ▶ “Peptide Based Nanoparticle-Platform for Extrahepatic Delivery of Functional mRNAs" Abstract: 761, May 8th ▶ " Peptide-Based Nanoparticles Mediated mRNA Rescue of Factor VIII; a New Approach to Treat Hemophilia A" Abstract : 1093, May 9th ▶ " In Vivo CRISPR Mediated Editing of PCSK9 Using Peptide-Based Nanoparticles Durably Lowers Cholesterol in Mice" Abstract : 1094, May 9th #p53 #KRAS #PCSK9 #CRISPR #nanotechnology #drugdelivery #mRNA #ASGCT #haemophilia #geneediting

This week DIVINCELL and Aanastra Inc will be at the American Association for Cancer Research Meeting 2024 in San Diego, CA. https://lnkd.in/g6P3g2CD Join Us on April 7th and 10th, We will be presenting our recent RNA Therapeutic work on : ▶ “In vivo rescue of p53 tumor suppressor function with ADGN-531 across Pan-p53 alterations” ▶ “Selective deletion of the KRAS mutant gene with ADGN-121 and ADGN-122 peptide-RNA nanoparticles: A new strategy to overcome acquired resistance to KRASG12C and KRASG12D small molecule inhibitors” ▶ “Peptide-mRNA complex mediated restoration of BRCA-1 tumor suppressor function in BRCA-1 mutated cancers as a new therapeutic strategy” #p53 #KRAS #PARPi #CRISPR #nanotechnology #drugdelivery #mRNA #cancer #AACR #BRCA-1 #geneediting